233 related articles for article (PubMed ID: 9255147)
1. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma.
Chung JK; Lee YJ; Jeong JM; Lee DS; Lee MC; Cho BY; Koh CS
J Nucl Med; 1997 Aug; 38(8):1191-5. PubMed ID: 9255147
[TBL] [Abstract][Full Text] [Related]
2. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
Cailleux AF; Baudin E; Travagli JP; Ricard M; Schlumberger M
J Clin Endocrinol Metab; 2000 Jan; 85(1):175-8. PubMed ID: 10634383
[TBL] [Abstract][Full Text] [Related]
3. Hepatic visualization on iodine-131 whole-body thyroid cancer scans.
Ziessman HA; Bahar H; Fahey FH; Dubiansky V
J Nucl Med; 1987 Sep; 28(9):1408-11. PubMed ID: 3625293
[TBL] [Abstract][Full Text] [Related]
4. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning.
Alzahrani AS; Bakheet S; Al Mandil M; Al-Hajjaj A; Almahfouz A; Al Haj A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5294-300. PubMed ID: 11701695
[TBL] [Abstract][Full Text] [Related]
5. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
Bajén MT; Mañé S; Muñoz A; García JR
J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans.
Omür O; Akgün A; Ozcan Z; Sen C; OzkiIiç H
Clin Nucl Med; 2009 Jan; 34(1):11-4. PubMed ID: 19092374
[TBL] [Abstract][Full Text] [Related]
7. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
Tatar FA; Morita E; Ituarte PH; Cavalieri RR; Duh QY; Price DC; Siperstein AE; Clark OH
World J Surg; 2001 Jun; 25(6):718-22. PubMed ID: 11376405
[TBL] [Abstract][Full Text] [Related]
8. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma.
Lubin E; Mechlis-Frish S; Zatz S; Shimoni A; Segal K; Avraham A; Levy R; Feinmesser R
J Nucl Med; 1994 Feb; 35(2):257-62. PubMed ID: 8294995
[TBL] [Abstract][Full Text] [Related]
9. Thallium-201 and iodine-131 scintigraphy in differentiated thyroid carcinoma.
Lorberboym M; Murthy S; Mechanick JI; Bergman D; Morris JC; Kim CK
J Nucl Med; 1996 Sep; 37(9):1487-91. PubMed ID: 8790199
[TBL] [Abstract][Full Text] [Related]
10. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
11. Thyroglobulin and 131I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy.
Moser E; Fritsch S; Braun S
Nucl Med Commun; 1988 Apr; 9(4):262-6. PubMed ID: 3399222
[TBL] [Abstract][Full Text] [Related]
12. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of diffuse hepatic visualization and thyroid bed uptake on post-ablative iodine-131 whole body scan in differentiated thyroid cancer.
Kim K; Kim SJ; Kim IJ; Kim YK; Kim BS; Pak K
Onkologie; 2012; 35(3):82-6. PubMed ID: 22414970
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of diffuse hepatic uptake on post-therapeutic early and delayed (131)I scan in differentiated thyroid cancer: a preliminary report.
Lee JW; Lee SM; Choi J
Ann Nucl Med; 2015 Feb; 29(2):190-7. PubMed ID: 25413273
[TBL] [Abstract][Full Text] [Related]
16. Iodine-131 uptake in inflammatory lung disease: a potential pitfall in treatment of thyroid carcinoma.
Höschl R; Choy DH; Gandevia B
J Nucl Med; 1988 May; 29(5):701-6. PubMed ID: 3373306
[TBL] [Abstract][Full Text] [Related]
17. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.
Grewal RK; Tuttle RM; Fox J; Borkar S; Chou JF; Gonen M; Strauss HW; Larson SM; Schöder H
J Nucl Med; 2010 Sep; 51(9):1361-7. PubMed ID: 20720058
[TBL] [Abstract][Full Text] [Related]
18. Complementary role of whole body scan and serum thyroglobulin determination in the follow-up of differentiated thyroid carcinoma.
Ronga G; Fiorentino A; Fragasso G; Fringuelli FM; Todino V
Ital J Surg Sci; 1986; 16(1):11-5. PubMed ID: 3087907
[TBL] [Abstract][Full Text] [Related]
19. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
20. Thyroglobulin radioimmunoassay and 131I scintigraphy in patients with differentiated thyroid carcinoma.
Lindegaard MW; Paus E; Høie J; Kullman G; Stenwig AE
Acta Chir Scand; 1988 Feb; 154(2):141-5. PubMed ID: 3354295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]